Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Wang, Tsai Yu ^a   Lin, Shu Min ^a   Shie, Shian Sen ^a   Chou, Pai Chien ^a   Huang, Chien Da ^a   Chung, Fu Tsai ^a   Kuo, Chih His ^a   Chang, Po Jui ^a   Kuo, Han Pin ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BACTERIUM CULTURE; CLINICAL FEATURE; CONCENTRATION RESPONSE; DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; GOUT; HUMAN; HYPERURICEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RASH; RETROSPECTIVE STUDY; THERAPY DELAY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84899641391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086316     Document Type: Article

References (21)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA: the journal of the American Medical Association 282: 677-686.
2. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, et al. (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. The New England journal of medicine 338: 1641-1649.
3. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. The New England journal of medicine 344: 1294-1303.
4. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, et al. (2009) Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 48: 179-185.
5. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR (2008) Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 168: 1984-1992.
6. Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. The American review of respiratory disease 133: 423-430. (Pubitemid 16126276)
7. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine 167: 603-662.
8. (1987) Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. The American review of respiratory disease 136: 1339-1342.
9. Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. (2008) Treatment of isoniazid-resistant pulmonary tuberculosis. BMC infectious diseases 8: 6.
10. Bang D, Andersen PH, Andersen AB, Thomsen VO (2010) Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. The Journal of infection 60: 452-457.
11. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J (2012) Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 16: 812-816.
12. Weber WW, Hein DW (1979) Clinical pharmacokinetics of isoniazid. Clinical pharmacokinetics 4: 401-422. (Pubitemid 10210049)
13. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, et al. (1963) Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull World Health Organ 29: 565-578.
14. Ando H, Kondo Y, Suetake T, Toyota E, Kato S, et al. (2010) Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 54: 1793-1799.
15. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA: the journal of the American Medical Association 283: 2537-2545.
16. Bloss E, Chan PC, Cheng NW, Wang KF, Yang SL, et al. (2012) Increasing directly observed therapy related to improved tuberculosis treatment outcomes in Taiwan. Int J Tuberc Lung Dis 16: 462-467.
17. Mushtaque A, Chowdhury R (1999) Success with the DOTS strategy. Lancet 353: 1003-1004.
18. Newell JN, Baral SC, Pande SB, Bam DS, Malla P (2006) Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 367: 903-909.
19. (1996) Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration. Lancet 347: 358-362.
20. (2004) Guidelines for chemotherapy of tuberculosis in Taiwan. J Microbiol Immunol Infect 37: 382-384.
21. Huang WL, Chen HY, Kuo YM, Jou R (2009) Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 47: 2520-2524.